The Phase 2 Istaroxime study was successful in multiple endpoints showing promise for how it may be utilized if approved in its targeted indications Primary endpoint of the study was met of increasing systolic blood pressure and demonstration of other benefits including no increase in heart rate and preserved renal function Partnership discussions with multiple potential partners that may fund the remainder of clinical development thus eliminating the Company's cash burn with the cardiovascular pipeline Pha ...